Targeting beta2-adrenoceptors for neuroprotection after cerebral ischemia: is inhibition or stimulation best?
Culmsee
Carsten
C
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001930:Brain Injuries / Q000209:etiology / Q000517:prevention & control*; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy*; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018343:Receptors, Adrenergic, beta-2 / Q000172:deficiency / Q000187:drug effects* / Q000235:genetics
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D018696:Neuroprotective Agents; D018343:Receptors, Adrenergic, beta-2